GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Indinavir

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Source-content exception: the live original page is empty apart from its heading. This does not establish a no-adjustment recommendation.

The separate CRIXIVAN label summary supplies actual historical dosing. It is not presented as missing text recovered from the original GlobalRPh page.

Check source scope before reading a dose

CRIXIVAN (indinavir sulfate) capsules

Product / population
Historical adult oral HIV product. Not an assertion of current U.S. marketing.
Renal method
Not specified
Source revision
05/2018
Retrieved
2026-09-05
Local review status
Historical exact U.S. label imported to fill the empty original source page; current availability is not established.
Official

CRIXIVAN (indinavir sulfate) capsules

Open original reference

NIH/NLM DailyMed - U.S. prescribing information · Historical adult oral HIV product. Not an assertion of current U.S. marketing.

Renal method: Not specified in this summary.
Source date: 05/2018
Retrieved: 2026-09-05

Historical exact U.S. label imported to fill the empty original source page; current availability is not established.

Historical labeled adult dose

The labeled adult regimen is 800 mg orally every 8 hours. Take with water, at least 1 hour before or 2 hours after a meal; a light meal is an alternative. Combination therapy and interacting medicines require separate review.

indinavir:dm-e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f-1 · Source locator: DOSAGE AND ADMINISTRATION; PDF page 25

Renal evidence and limitations

The label reports no renal-impairment pharmacokinetic study and supplies no numeric renal-adjustment table. Removal by hemodialysis or peritoneal dialysis is unknown. Nephrolithiasis or urolithiasis may require temporary interruption for 1-3 days or discontinuation, with clinical management of hydration.

indinavir:dm-e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f-2 · Source locator: CLINICAL PHARMACOLOGY; WARNINGS; OVERDOSAGE; DOSAGE AND ADMINISTRATION

Source-specific limits

Selected product data list a marketing end date of October 24, 2021. This is an archived label, not a new-drug addition.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f
Retrieved
2026-09-05
Exact label title
CRIXIVAN (indinavir sulfate) capsules
DailyMed Set ID
e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f
Labeler
Merck Sharp & Dohme LLC
DailyMed page updated
2023-01 (SPL product-data revision)
Label revision
05/2018
FDA application
NDA020685
U.S. product identity basis
Exact named product and route appear in the selected U.S. prescription label; current retail availability was not independently assessed.
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
877cc416631e365cd6821dc4def4d3df7aabed6b1986bc0eee8e6d2925877522

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=indinavir&s1=dm-e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f&h1=215e6e6a12203efed2c53411fa70e1a2b6f281a0738d823e3a376c1db3290cf0